Home The Word Brain My Amedeo FAQ Privacy About   


Amedeo C49

English + 你好 (nǐ hǎo) = limitless possibilities.
Start learning Mandarin Chinese today—for free, forever.

Amedeo C49 is completely free, for life. Next week: +49.


  Prostate Cancer

  Free Subscription


Articles published in Cancer Lett

Retrieve available abstracts of 28 articles:
HTML format



Single Articles


    June 2025
  1. ZHANG M, Xu Z, Cao Y, Gao C, et al
    Analysis and characterization of extrachromosomal circular DNA in prostate cancer: Potential biomarker discovery from urine, plasma, and tumor samples.
    Cancer Lett. 2025;628:217875.
    PubMed     Abstract available


    May 2025
  2. JIANG H, Zeng Y, Ning W, Hong J, et al
    Ketogenesis instigates immune suppression in enzalutamide resistant prostate cancer via OTUD7B beta-hydroxybutyrylation.
    Cancer Lett. 2025 May 18:217808. doi: 10.1016/j.canlet.2025.217808.
    PubMed     Abstract available


    April 2025
  3. CAI S, Deng Y, Zou Z, Tian W, et al
    Metformin inhibits the progression of castration resistant prostate cancer by regulating PDE6D induced purine metabolic alternation and cGMP / PKG pathway activation.
    Cancer Lett. 2025 Apr 9:217694. doi: 10.1016/j.canlet.2025.217694.
    PubMed     Abstract available


    February 2025
  4. CHAN HY, Wang Q, Howie A, Bucci J, et al
    Extracellular vesicle biomarkers redefine prostate cancer radiotherapy.
    Cancer Lett. 2025 Feb 18:217568. doi: 10.1016/j.canlet.2025.217568.
    PubMed     Abstract available


  5. SUBRAMANIAM S, Jeet V, Gunter JH, Clements JA, et al
    Lactoferrin-Encapsulated Dichloroacetophenone (DAP) nanoparticles enhance drug delivery and anti-tumor efficacy in prostate cancer.
    Cancer Lett. 2025 Feb 7:217522. doi: 10.1016/j.canlet.2025.217522.
    PubMed     Abstract available


    January 2025
  6. HINDES MT, McElligott AM, Best OG, Ward MP, et al
    Metabolic reprogramming, malignant transformation and metastasis: lessons from chronic lymphocytic leukaemia and prostate cancer.
    Cancer Lett. 2025 Jan 2:217441. doi: 10.1016/j.canlet.2025.217441.
    PubMed     Abstract available


    November 2024
  7. LIU R, Zou Z, Zhang Z, He H, et al
    Evaluation of glucocorticoid-related genes reveals GPD1 as a therapeutic target and regulator of sphingosine 1-phosphate metabolism in CRPC.
    Cancer Lett. 2024;605:217286.
    PubMed     Abstract available


  8. MUNIYAN S, Vengoji R, Nimmakayala RK, Seshacharyulu P, et al
    PAF1-mediated transcriptional reprogramming confers docetaxel resistance in advanced prostate cancer.
    Cancer Lett. 2024 Nov 25:217355. doi: 10.1016/j.canlet.2024.217355.
    PubMed     Abstract available


  9. STEINER L, Eldh M, Offens A, Veerman RE, et al
    Protein profile in urinary extracellular vesicles is a marker of malignancy and correlates with muscle invasiveness in urinary bladder cancer.
    Cancer Lett. 2024;609:217352.
    PubMed     Abstract available


    October 2024
  10. GURUVAYURAPPAN GK, Frankenbach-Desor T, Laubach M, Klein A, et al
    Clinical Challenges in Prostate Cancer Management: Metastatic Bone-tropism and The Role of Circulating Tumor Cells.
    Cancer Lett. 2024 Oct 30:217310. doi: 10.1016/j.canlet.2024.217310.
    PubMed     Abstract available


    August 2024
  11. HE Q, Zhang Y, Li W, Chen S, et al
    Inhibition of PRMT5 moderately suppresses prostate cancer growth in vivo but enhances its response to immunotherapy.
    Cancer Lett. 2024;602:217214.
    PubMed     Abstract available


  12. WANG X, Zhang L, Cheng L, Wang Y, et al
    Extracellular Vesicle-derived Biomarkers in Prostate Cancer Care: Opportunities and Challenges.
    Cancer Lett. 2024 Aug 12:217184. doi: 10.1016/j.canlet.2024.217184.
    PubMed     Abstract available


  13. LIU D, Wang L, Guo Y
    Advances in and Prospects of Immunotherapy for Prostate Cancer.
    Cancer Lett. 2024 Aug 8:217155. doi: 10.1016/j.canlet.2024.217155.
    PubMed     Abstract available


    June 2024
  14. LIU YN, Liu MK, Wen YC, Li CH, et al
    Binding of interleukin-1 receptor antagonist to cholinergic receptor muscarinic 4 promotes immunosuppression and neuroendocrine differentiation in prostate cancer.
    Cancer Lett. 2024 Jun 28:217090. doi: 10.1016/j.canlet.2024.217090.
    PubMed     Abstract available


  15. CLARK A, Villarreal MR, Huang SB, Jayamohan S, et al
    Targeting S6K/NFkappaB/SQSTM1/Poltheta signaling to suppress radiation resistance in Prostate Cancer.
    Cancer Lett. 2024 Jun 24:217063. doi: 10.1016/j.canlet.2024.217063.
    PubMed     Abstract available


  16. LIU C, Chen J, Cong Y, Chen K, et al
    PROX1 drives neuroendocrine plasticity and liver metastases in prostate cancer.
    Cancer Lett. 2024 Jun 18:217068. doi: 10.1016/j.canlet.2024.217068.
    PubMed     Abstract available


  17. CHEN HJ, Yu MM, Huang JC, Lan FY, et al
    SLC4A4 is a novel driver of enzalutamide resistance in prostate cancer.
    Cancer Lett. 2024 Jun 14:217070. doi: 10.1016/j.canlet.2024.217070.
    PubMed     Abstract available


    May 2024
  18. KAUSHAL JB, Takkar S, Batra SK, Siddiqui JA, et al
    Diverse landscape of genetically engineered mouse models: Genomic and molecular insights into prostate cancer.
    Cancer Lett. 2024;593:216954.
    PubMed     Abstract available


    March 2024
  19. KANAOKA S, Okabe A, Kanesaka M, Rahmutulla B, et al
    Chromatin activation with H3K36me2 and compartment shift in metastatic castration-resistant prostate cancer.
    Cancer Lett. 2024;588:216815.
    PubMed     Abstract available


  20. RODRIGO-FAUS M, Vincelle-Nieto A, Vidal N, Puente J, et al
    CRISPR/Cas9 screenings unearth protein arginine methyltransferase 7 as a novel essential gene in prostate cancer metastasis.
    Cancer Lett. 2024 Mar 1:216776. doi: 10.1016/j.canlet.2024.216776.
    PubMed     Abstract available


    February 2024
  21. WEI Z, Zhang C, Song Y, Han D, et al
    CircUBE3A(2,3,4,5) promotes adenylate-uridylate-rich binding factor 1 nuclear translocation to suppress prostate cancer metastasis.
    Cancer Lett. 2024 Feb 27:216743. doi: 10.1016/j.canlet.2024.216743.
    PubMed     Abstract available


  22. YIN W, Chen G, Li Y, Li R, et al
    Identification of a 9-gene signature to enhance biochemical recurrence prediction in primary prostate cancer: A benchmarking study using ten machine learning methods and twelve patient cohorts.
    Cancer Lett. 2024 Feb 21:216739. doi: 10.1016/j.canlet.2024.216739.
    PubMed     Abstract available


  23. CHEN H, Dong K, Ding J, Xia J, et al
    CRISPR genome-wide screening identifies PAK1 as a critical driver of ARSI cross-resistance in prostate cancer progression.
    Cancer Lett. 2024 Feb 14:216725. doi: 10.1016/j.canlet.2024.216725.
    PubMed     Abstract available


  24. ZHAO G, Forn-Cuni G, Scheers M, Lindenbergh PP, et al
    Simultaneous targeting of AMPK and mTOR is a novel therapeutic strategy against prostate cancer.
    Cancer Lett. 2024 Feb 7:216657. doi: 10.1016/j.canlet.2024.216657.
    PubMed     Abstract available


    January 2024
  25. SAEZ-MARTINEZ P, Porcel-Pastrana F, Montero-Hidalgo AJ, Lozano de la Haba S, et al
    Dysregulation of RNA-Exosome machinery is directly linked to major cancer hallmarks in prostate cancer: Oncogenic role of PABPN1.
    Cancer Lett. 2024 Jan 18:216604. doi: 10.1016/j.canlet.2023.216604.
    PubMed     Abstract available


    November 2023
  26. ALSAMRAAE M, Costanzo-Garvey D, Teply BA, Boyle S, et al
    Androgen receptor inhibition suppresses anti-tumor neutrophil response against bone metastatic prostate cancer via regulation of TbetaRI expression.
    Cancer Lett. 2023 Nov 6:216468. doi: 10.1016/j.canlet.2023.216468.
    PubMed     Abstract available


    October 2023
  27. WANG C, Wang T, Li KJ, Hu LH, et al
    SETD4 inhibits prostate cancer development by promoting H3K27me3-mediated NUPR1 transcriptional repression and cell cycle arrest.
    Cancer Lett. 2023 Oct 23:216464. doi: 10.1016/j.canlet.2023.216464.
    PubMed     Abstract available


    September 2023
  28. SLOOTBEEK PHJ, Overbeek JK, Ligtenberg MJL, van Erp NP, et al
    PARPing up the right tree; an overview of PARP inhibitors for metastatic castration-resistant prostate cancer.
    Cancer Lett. 2023 Sep 7:216367. doi: 10.1016/j.canlet.2023.216367.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Prostate Cancer is free of charge.